Cardiome gets $15M for vernakalant submission

Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME) said it earned a US$15 million milestone payment after partner Merck & Co. Inc. (NYSE:MRK) submitted an MAA to EMEA for IV vernakalant to treat atrial fibr...